Asian Pacific Journal of Cancer Prevention

  • 제15권16호
  • /
  • Pages.6559-6564
  • /
  • 2014
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Efficacy and Safety of Bevacizumab in Chinese Patients with Metastatic Colorectal Cancer

  • Zhu, Li-Ming (Department of Gastrointestinal Medical Oncology, Zhejiang Cancer Hospital) ;
  • Zhao, Ya-Zhen (Department of Gastrointestinal Medical Oncology, Zhejiang Cancer Hospital) ;
  • Ju, Hai-Xing (Department of Surgery, Zhejiang Cancer Hospital) ;
  • Liu, Lu-Ying (Department of Radiotherapy, Zhejiang Cancer Hospital) ;
  • Chen, Lei (Department of Gastrointestinal Medical Oncology, Zhejiang Cancer Hospital) ;
  • Liu, Bi-Xia (Department of Gastrointestinal Medical Oncology, Zhejiang Cancer Hospital) ;
  • Xu, Qi (Department of Gastrointestinal Medical Oncology, Zhejiang Cancer Hospital) ;
  • Luo, Cong (Department of Gastrointestinal Medical Oncology, Zhejiang Cancer Hospital) ;
  • Ying, Jie-Er (Department of Gastrointestinal Medical Oncology, Zhejiang Cancer Hospital) ;
  • Yang, Yun-Shan (Department of Gastrointestinal Medical Oncology, Zhejiang Cancer Hospital) ;
  • Zhong, Hai-Jun (Department of Gastrointestinal Medical Oncology, Zhejiang Cancer Hospital)
  • 발행 : 2014.08.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective: To evaluate the efficacy and safety of bevacizumab in the treatment of patients with metastatic colorectal cancer (mCRC). Methods: In a single-center, observational study of 91 Chinese patients with mCRC who received bevacizumab in combination with chemotherapy was conducted. Objective response rates (ORRs), progression-free survival (PFS), overall survival (OS) and adverse events were recorded, and the relationships between various clinical factors and PFS or OS were evaluated by Cox proportional hazards models. Results: Treatment with bevacizumab and chemotherapy was effective and tolerable. Univariate analysis showed that PFS and OS were significantly associated with the Eastern Cooperative Oncology Group performance status (ECOG-PS) score, duration of bevacizumab exposure, and whether chemotherapy was continued after discontinuation of bevacizumab treatment. A multivariate analysis showed that the duration of bevacizumab exposure and whether chemotherapy was continued after discontinuation of bevacizumab were independent prognostic factors for PFS and OS. Conclusion: In Chinese mCRC population, the shorter the duration of exposure to bevacizumab and chemotherapy, the worse the prognosis is.

키워드

참고문헌

  1. Adams RA, Meade AM, Seymour MT, et al (2011). Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol, 12, 642-53. https://doi.org/10.1016/S1470-2045(11)70102-4
  2. Bendell JC, Bekaii-Saab TS, Cohn AL, et al (2012). Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOXbevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist, 17, 1486-95. https://doi.org/10.1634/theoncologist.2012-0190
  3. Bennouna J, Sastre J, Arnold D, et al (2013). Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol, 14, 29-37. https://doi.org/10.1016/S1470-2045(12)70477-1
  4. Colucci G, Gebbia V, Paoletti G (2005). Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol, 23, 4866-75. https://doi.org/10.1200/JCO.2005.07.113
  5. Chen HX, Mooney M, Boron M, et al (2006). Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol, 24, 3354-60. https://doi.org/10.1200/JCO.2005.05.1573
  6. Chibaudel B, Maindrault-Goebel F, Lledo G, et al (2009). Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol, 27, 5727-33. https://doi.org/10.1200/JCO.2009.23.4344
  7. Cunningham D, Lang I, Marcuello E, et al (2013). Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol, 14, 1077-85. https://doi.org/10.1016/S1470-2045(13)70154-2
  8. Dirican A, Varol U, Kucukzeybek Y, et al (2014). Treatment of metastatic colorectal cancer with or without bevacizumab: can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab? Asian Pac J Cancer Prev, 15, 4781-6. https://doi.org/10.7314/APJCP.2014.15.12.4781
  9. Douillard JY, Siena S, Cassidy J, et al (2010). Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol, 28, 4697-705. https://doi.org/10.1200/JCO.2009.27.4860
  10. Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47. https://doi.org/10.1016/j.ejca.2008.10.026
  11. Giantonio BJ, Catalano PJ, Meropol NJ, et al (2007). Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol, 25, 1539-44. https://doi.org/10.1200/JCO.2006.09.6305
  12. Guan ZZ, Xu JM, Luo RC, et al (2011). Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chin J Cancer, 30, 682-9. https://doi.org/10.5732/cjc.011.10188
  13. Hurwitz H, Fehrenbacher L, Novotny W, et al (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350, 2335-42. https://doi.org/10.1056/NEJMoa032691
  14. Kopetz S, Chang GJ, Overman MJ, et al (2009). Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol, 27, 3677-83. https://doi.org/10.1200/JCO.2008.20.5278
  15. Kozloff M, Yood MU, Berlin J, et al (2009). Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study. Oncologist, 14, 862-70. https://doi.org/10.1634/theoncologist.2009-0071
  16. Kang BW, Kim TW, Lee JL, et al (2009). Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis. Med Onvcol, 26, 32-7.
  17. Koopman M, Simkens LH, Ten Tije AJ, et al (2013). Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): the phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG). J Clin Oncol, 31, Abstract 3502.
  18. Koeberle D, Betticher DC, Von Moos R, et al (2013). Bevacizumab continuation versus no continuation after firstline chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized phase III noninferiority trial (SAKK 41/06). J Clin Oncol, 31, Abstract 3503.
  19. Park LC, Lee HS, Shin SH, et al (2012). Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer. World J Gastroenterol, 18, 1104-9. https://doi.org/10.3748/wjg.v18.i10.1104
  20. Saltz LB, Clarke S, Diaz-Rubio E, et al (2008). Bevacizumab in combination with oxaliplatin-based chemotherapy as firstline therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol, 26, 2013-9. https://doi.org/10.1200/JCO.2007.14.9930
  21. Stangl R, Altendorf-Hofmann A, Charnley RM, et al (1994). Factors influencing the natural history of colorectal liver metastases. Lancet, 343, 1405-10. https://doi.org/10.1016/S0140-6736(94)92529-1
  22. Van Cutsem E, Kohne CH, Hitre E, et al (2009). Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med, 360, 1408-17. https://doi.org/10.1056/NEJMoa0805019
  23. Van Cutsem E, Rivera F, Berry S, et al (2009). Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol, 20, 1842-7. https://doi.org/10.1093/annonc/mdp233
  24. Wu Q, Shi Y, Chen L, et al (2013). Effect and safety of bevacizumab-containing chemotherapy treatment in Chinese patients with metastatic colorectal cancer. Onco Targets Ther, 6, 485-90.

피인용 문헌

  1. XELOX Plus Bevacizumab vs. FOLFIRI Plus Bevacizumab Treatment for First-line Chemotherapy in Metastatic Colon Cancer: a Retrospective Study of the Anatolian Society of Medical Oncology vol.15, pp.23, 2014, https://doi.org/10.7314/APJCP.2014.15.23.10375
  2. Endothelial Cell Proliferation and Vascular Endothelial Growth Factor Expression in Primary Colorectal Cancer and Corresponding Liver Metastases vol.16, pp.11, 2015, https://doi.org/10.7314/APJCP.2015.16.11.4549
  3. Effects of a Multikinase Inhibitor Motesanib (AMG 706) Alone and Combined with the Selective DuP-697 COX-2 Inhibitor on Colorectal Cancer Cells vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.1103